Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.
Pieris Pharmaceuticals, Inc. (PIRS) delivers innovative biopharmaceutical solutions through its proprietary anticalin protein platform. This dedicated news hub provides investors and industry stakeholders with essential updates on clinical developments, strategic collaborations, and therapeutic advancements.
Track critical updates including clinical trial progress in immuno-oncology and respiratory therapies, partnership announcements with global pharmaceutical leaders, and regulatory milestones for novel anticalin-based treatments. Our curated news collection serves as a centralized resource for understanding PIRS's role in advancing precision-targeted therapeutics.
Discover timely updates on pipeline developments across key therapeutic areas and business strategy implementations. This repository is designed to help users monitor the company's progress in translating innovative protein engineering into clinical-stage assets.
Bookmark this page for streamlined access to Pieris Pharmaceuticals' latest announcements and scientific breakthroughs. Regularly updated to ensure you stay informed about this clinical-stage biotech innovator's evolving landscape.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) announced an upcoming investor call on November 2, 2022, at 8:00 AM EDT. The call will focus on third-quarter 2022 financial results and corporate updates. Participants can join the call by dialing (888) 645-4404 (Toll Free) or (862) 298-0702 (International). A listen-only audio webcast will also be available here. For those unable to attend, a replay will be accessible on the company's website.
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotech firm, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 12:30 PM EDT. The presentation will highlight its proprietary Anticalin technology for treating respiratory diseases and cancer. A webcast will be available here. The company focuses on developing inhalable Anticalin proteins and locally-activated bispecifics for improved clinical outcomes. For more details, visit www.pieris.com.
Pieris Pharmaceuticals (NASDAQ:PIRS) has announced the presentation of preclinical data for its inhaled drug candidate PRS-400 at the ERS International Congress 2022. This candidate targets muco-obstructive lung diseases by inhibiting Jagged-1, a protein involved in mucus regulation. Preclinical results indicate that PRS-400 effectively reduces mucin expression and goblet cell presence in models of airway inflammation. Pieris aims to leverage these findings to advance PRS-400 and its Anticalin technology for broader respiratory disease applications.
Pieris Pharmaceuticals reported its Q2 2022 financial results, revealing a net loss of $10.3 million, or $(0.14) per share, an improvement from a loss of $15.5 million in Q2 2021. The company is adjusting its PRS-060/AZD1402 trial design to boost enrollment and aims for topline results by Q3 2023. Pieris will cease enrollment in the cinrebafusp alfa study to prioritize resources. The company has submitted regulatory filings for PRS-220 and anticipates dosing the first patient later this year, with cash reserves expected to fund operations until Q2 2024.
Pieris Pharmaceuticals (NASDAQ:PIRS) will host a second quarter 2022 investor call on August 4, 2022, at 8:00 AM EDT. The call will cover financial results and provide a corporate update. Participants can join by dialing (800) 285-6670 for US & Canada or (713) 481-1320 internationally, at least five minutes prior. A listen-only audio webcast will also be available. A replay will be posted on the company’s website for those unable to attend. For more information, visit pieris.com.
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotechnology company, announced its management will present at the Jefferies Healthcare Conference on June 8, 2022, at 8:00 AM EDT. The presentation will showcase their innovative Anticalin technology aimed at treating respiratory diseases and cancer.
The company specializes in developing biotherapeutics, including inhalable Anticalin proteins and locally-activated bispecifics for immuno-oncology. A webcast of the presentation will be available via their website.
Pieris Pharmaceuticals (NASDAQ:PIRS) will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 9:30 AM EDT. The presentation will be available via webcast at the provided link. The company focuses on developing innovative biotherapeutics using its unique Anticalin technology platform, targeting respiratory diseases and cancer. Pieris aims to create inhalable Anticalin proteins for respiratory issues and bispecifics for immuno-oncology, showcasing its commitment to delivering superior clinical outcomes.
Pieris Pharmaceuticals (NASDAQ: PIRS) reported its first-quarter financial results for 2022, revealing revenues of $10.99 million, down from $15.63 million in Q1 2021. The company's net loss was $5.1 million or $(0.07) per share, consistent with the previous year's loss. Cash reserves decreased to $100.3 million. Despite challenges affecting clinical enrollments, Pieris remains committed to advancing its pipeline, including the IND filing for PRS-342/BOS-342 expected within the next 12 months and ongoing collaborations with AstraZeneca.
BOSTON, MA / ACCESSWIRE / May 4, 2022 - Pieris Pharmaceuticals (NASDAQ:PIRS) will host a first quarter 2022 investor call on May 11, 2022, at 8:00 AM EDT. The call will cover financial results and provide a corporate update.
Participants can join by dialing (888) 428-7458 for the US or (862) 298-0702 internationally, or listen via a webcast here. A replay will be available after the call on the company's website.
Pieris Pharmaceuticals reported financial results for the year ended December 31, 2021, revealing a net loss of $45.7 million or $(0.71) per share. Cash and equivalents reached $117.8 million, an increase from $70.4 million in 2020, supported by collaboration agreements and an ATM program raising $38.5M. The company initiated several clinical trials, including phase 2 studies of PRS-060/AZD1402 and cinrebafusp alfa, with topline data expected this year. The R&D expense rose to $66.7 million, reflecting higher spending on multiple programs.
